IP Library › Granted Patent US 12,202,785
Granted Patent B2
US 12,202,785 · App. 18/059,533 · Granted Jan 21, 2025

Modified tetracycline for treatment of alcohol use disorder, pain and other disorders involving potential inflammatory processes

Inventors: Susan E. Bergeson (Lubbock, TX); Peter Syapin (Camarillo, CA); Ted W. Reid (Wolfforth, TX); Mayank Shastri (Lubbock, TX); Phat Tran (Lubbock, TX)
Assignee: TEXAS TECH UNIVERSITY SYSTEM
C07C237/26A61B5/4848A61K31/65C07D317/72C07C2603/46
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,202,785
App. No.
18/059,533
Granted
Jan 21, 2025
Kind
B2
Abstract

A method of treating Alcohol Use Disorder (AUD), Substance Use Disorder (SUD), tobacco use, pain, or proinflammatory disorders comprising: providing a subject with an effective amount of a modified tetracycline or derivative thereof to ameliorate or eliminate the AUD, SUD, tobacco use, pain, or proinflammatory disorder, and wherein the modified tetracycline or derivative thereof has reduced binding to a microbial ribosome and has the formula: wherein R1 is acetyl, R2 is OH or acetyl, R3 is acetyl, R4 is H or acetyl, and R5 is acetyl.

Claims (29)

1. A method of treating a Substance Use Disorder (SUD), or pain comprising:

providing a subject with an effective amount of a modified tetracycline or derivative thereof to ameliorate the AUD, SUD, tobacco use, or pain, and wherein the modified tetracycline or derivative thereof has reduced binding to a microbial ribosome and has the formula:

R 1 is methyl, ethyl, propyl, butyl, acetyl, R 2 is H or acetyl, R 3 is H or acetyl, R 4 is H or acetyl, and R 5 is H or acetyl.

2. The method of claim 1 , wherein the modified tetracycline has the formula:

3. The method of claim 1 , wherein the modified tetracycline has at least one of: moderate to no antibacterial activity, or has moderate to no antifungal activity.

4. The method of claim 1 , wherein the ribosome is a bacterial ribosome.

5. The method of claim 1 , wherein the modification at least one of: produces steric hindrance, blocks hydrogen bonding, or change coordination with divalent cations.

6. The method of claim 1 , wherein the modified tetracycline further comprises a pharmaceutically acceptable buffer, excipient, filler, or carrier.

7. The method of claim 1 , wherein the modified tetracycline is adapted for administration orally, enterally, parenterally, intramuscularly, intravenously, or intraperitoneally.

8. A method of evaluating a candidate drug believed to be useful in treating a Substance Use Disorder (SUD) or pain, the method comprising:

a) measuring the SUD or pain from a set of patients;

b) administering a candidate drug to a first subset of the patients, and a placebo to a second subset of the patients, wherein the candidate drug is a C6′ modified tetracycline that has the formula:

R 1 is methyl, ethyl, propyl, butyl, acetyl, R 2 is H or acetyl, R 3 is H or acetyl, R 4 is H or acetyl, and R 5 is H or acetyl;

c) repeating step a) after the administration of the candidate drug or the placebo; and

d) determining if the candidate drug reduces the SUD or pain that is statistically significant as compared to any reduction occurring in the second subset of patients, wherein a statistically significant reduction indicates that the candidate drug is useful in treating SUD or pain.

9. The method of claim 8 , wherein the modified tetracycline has the formula:

10. The method of claim 8 , wherein the modification at least one of: produces steric hindrance, blocks hydrogen bonding, or change coordination with divalent cations.

11. A method of treating a Substance Use Disorder (SUD), or pain comprising:

identifying a subject in need of treatment for the SUD or pain; and

providing the subject with an effective amount of a modified tetracycline or derivative thereof to ameliorate the SUD or pain, and wherein the modified tetracycline or derivative thereof has reduced binding to a microbial ribosome and has the formula:

R 1 is methyl, ethyl, propyl, butyl, acetyl, R 2 is OH or acetyl, R 3 is H or acetyl, R 4 is H or acetyl, and R 5 is H or acetyl, in a pharmaceutically acceptable carrier.

12. The method of claim 11 , wherein the modified tetracycline has the formula:

13. The method of claim 11 , wherein the modified tetracycline has at least one of: moderate to no antibacterial activity, or has moderate to no antifungal activity.

14. The method of claim 11 , wherein the ribosome is a bacterial ribosome.

15. The method of claim 11 , wherein the modification at least one of: produces steric hindrance, blocks hydrogen bonding, or change coordination with divalent cations.

16. The method of claim 11 , wherein the modified tetracycline further comprises a pharmaceutically acceptable buffer, excipient, filler, or carrier.

17. The method of claim 11 , wherein the modified tetracycline is adapted for administration orally, enterally, intramuscularly, parenterally, intravenously, or intraperitoneally.

18. A method of treating a Substance Use Disorder (SUD) or pain comprising:

providing a subject with an effective amount of a modified tetracycline or derivative thereof to ameliorate the SUD, or pain, and wherein the modified tetracycline or derivative thereof has reduced binding to a microbial ribosome and has the formula selected from:

Assignments (3)
CONFIRMATORY LICENSE Recorded Jan 9, 2024
From: TEXAS TECH UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 066253/0801 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CITY SHOULD READ LUBBOCK PREVIOUSLY RECORDED AT REEL: 062505 FRAME: 0688. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jan 30, 2023
From: BERGESON, SUSAN E.; SYAPIN, PETER; REID, TED W.; SHASTRI, MAYANK; TRAN, PHAT
To: TEXAS TECH UNIVERSITY SYSTEM
Reel/Frame 062540/0467 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 27, 2023
From: BERGESON, SUSAN E.; SYAPIN, PETER; REID, TED W.; SHASTRI, MAYANK; TRAN, PHAT
To: TEXAS TECH UNIVERSITY SYSTEM
Reel/Frame 062505/0668 →
Continuity (4)
Continuation 16973896
Provisional Application 62684467 · Jun 13, 2018
Provisional Application 62684509 · Jun 13, 2018
Related Publication 20230127462A1 · Apr 27, 2023
References Cited (33)
US 20030166585A1 · Drapper et al. · 2003 [cited by applicant]
US 20040063674A1 · Levy et al. · 2004 [cited by applicant]
US 20050048574A1 · Kantor et al. · 2005 [cited by applicant]
US 20070093455A1 · Abato et al. · 2007 [cited by applicant]
US 20100173991A1 · Lorenz et al. · 2010 [cited by applicant]
US 20140155357A1 · Abato et al. · 2014 [cited by applicant]
US 20150377894A1 · Helson · 2015 [cited by applicant]
US 20170144979A1 · Duncan et al. · 2017 [cited by applicant]
US 20220040208A1 · Bergeson et al. · 2022 [cited by applicant]
EP 2659887A1 · 2013 [cited by applicant]
WO 03005971A2 · 2003 [cited by applicant]
WO 2004006850A2 · 2004 [cited by applicant]
WO 2004064728A2 · 2004 [cited by applicant]
WO 2005112945A2 · 2005 [cited by applicant]
WO 2009012741A1 · 2009 [cited by applicant]
WO 0305971A2 · 2023 [cited by applicant]
Agrawal, R. G. et al. 2011. “Minocycline reduces ethanol drinking”, Brain, behavior, and immunity, 25 Suppl 1: S165-9. [cited by applicant]
Agrawal, R. G. et al. 2014. “Bioinformatics analyses reveal age-specific neuroimmune modulation as a target for treatment of high ethanol drinking”, Alcoholism, clinical and experimental research, 38: 428-37. [cited by applicant]
Bergeson, S. E. et al. 2016. “Binge Ethanol Consumption Increases Inflammatory Pain Responses and Mechanical and Cold Sensitivity: Tigecycline Treatment Efficacy Shows Sex Differences”, Alcoholism, clinical and experime… [cited by applicant]
Bergeson, S. E. et al. 2016. 'Tigecycline Reduces Ethanol Intake in Dependent and Nondependent Male and Female C57BL/6J Mice', Alcoholism, clinical and experimental research, 40: 2491-98. [cited by applicant]
Blednov, Y. A. et al. 2011. “Activation of inflammatory signaling by lipopolysaccharide produces a prolonged increase of voluntary alcohol intake in mice”, Brain, behavior, and immunity, 25 Suppl 1: S92-S105. [cited by applicant]
Craig, R.G. et al. “A chemically modified tetracycline inhibits streptozotocin-induceddiabetic depression of skin collagen synthesis and steady-state type I procollagen mRNA.” Biochim BioRhY.S Acta. Apr. 2, 19984; 1402(… [cited by applicant]
Griffin, Michael O. et al. “Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature”, Am J Physiol Cell Physiol. Sep. 2010; 299(3): C539-C548. [cited by applicant]
Hutchinson, Mark R. et al. “Minocycline suppresses morphine-induced respiratory depression, suppresses morphine- Induced reward, and enhances systemic morphine-induced analgesia”, Brain, Behavior and Immunity 22(8): 124… [cited by applicant]
International Search Report [Isa/US] PCT/US2019/036892 dated Sep. 17, 2019. [cited by applicant]
International Search Report [Isa/US] PCT/US2019/036928 dated Aug. 27, 2019. [cited by applicant]
Lew, Michael A. et al. “Antifungal Activity of Four Tetracycline Analogues against Candida albicans in Vitro: Potentiation by Amphotericin B” The Journal of Infectious Diseases, vol. 136, Issue 2, Aug. 1977, pp. 263-270. [cited by applicant]
Liy, Yu et al. “A Chemically Modified Tetracycline (CMT-3) Is a New Antifungal Agent” Antimicrobial Agents and Chemotherapy, May 2002, p. 1447-1454. [cited by applicant]
Martinez, J. M. et al. 2016. “Effective Reduction of Acute Ethanol Withdrawal by the Tetracycline Derivative, Tigecycline, in Female and Male DBA/2J Mice”, Alcoholism, clinical and experimental research, 40: 2499-505. [cited by applicant]
Montesinos, J. et al. 2016. “Impact of the Innate Immune Response in the Actions of Ethanol on the Central Nervous System”, Alcoholism, clinical and experimental research, 40: 2260-70. [cited by applicant]
Rhodes, J. S. et al. 2005. “Evaluation of a simple model of ethanol drinking to intoxication in C57BL/6J mice”, Physiology & Behavior, 84: 53-63. [cited by applicant]
Schedlbauer, A. et al. 2015. “Structural characterization of an alternative mode of tigecycline binding to the bacterial ribosome”, Antimicrobial agents and chemotherapy, 59: 2849-54. [cited by applicant]
Syapin, P. J. et al. 2016. “Effective Reduction in High Ethanol Drinking by Semisynthetic Tetracycline Derivatives”, Alcoholism, clinical and experimental research, 40: 2482-90. [cited by applicant]